Amylin
A pancreatic hormone co-released with insulin that promotes fullness and slows digestion — the next frontier after GLP-1.
Amylin is secreted alongside insulin at every meal and completes the satiety picture: it slows gastric emptying, suppresses glucagon, and signals fullness through brainstem pathways distinct from GLP-1's. People with type 2 diabetes often secrete too little of it.
The hormone resisted drug development for decades because it clumps into unstable aggregates, but long-acting analogs cracked the problem — first pramlintide for diabetes, now cagrilintide for weight. Because amylin and GLP-1 reach appetite through different doors, combining them (as in CagriSema) stacks their effects, which is why "amylin" is the word to watch in next-generation weight medicine.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Amylin? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment